The deal would help secure enough COVID-19 vaccine doses – when the shots have been developed – for poor countries to immunise healthcare workers and those at high risk, it said, as well as creating a “buffer of doses” for use when needed.
More than 100 vaccine candidates against SARS-CoV-2 are in development, with about 12 in human testing designed mainly to evaluate safety.
Experts have predicted that a successful vaccine will take more than a year to develop and companies and governments are pouring money into dozens of programmes as their best hope of allowing a durable escape from lockdowns and get economies expanding again.
About Gavi, the Vaccine Alliance
Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world’s children against some of the world’s deadliest diseases. Since its inception in 2000, Gavi has helped to immunise a whole generation – over 760 million children – and prevented more than 13 million deaths, helping to halve child mortality in 73 developing countries.
Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningitis and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation and reaching the unvaccinated children still being left behind, employing innovative finance and the latest technology – from drones to biometrics – to save millions more lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency
